Topical tofacitinib for the management of lymphocytic-variant hypereosinophilic syndrome with cutaneous involvement.

Said, Jordan T; Elman, Scott A; Tawa, Marianne; Fisher, David C; Merola, Joseph F; Kupper, Thomas S

Said, Jordan T; Elman, Scott A; Tawa, Marianne; Fisher, David C; Merola, Joseph F; Kupper, Thomas S.

Afiliação

Said JT; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Elman SA; Harvard Medical School, Boston, Massachusetts, USA.
Tawa M; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Fisher DC; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Merola JF; Harvard Medical School, Boston, Massachusetts, USA.
Kupper TS; Medical Oncology/Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Dermatol Ther ; 35(7): e15518, 2022 07.

Article em En | MEDLINE | ID: mdl-35426208

Assuntos

Síndrome Hipereosinofílica; Humanos; Síndrome Hipereosinofílica/diagnóstico; Síndrome Hipereosinofílica/tratamento farmacológico; Piperidinas; Pirimidinas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome Hipereosinofílica Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google